title: [Solitary bone plasmocytoma: treatment and outcome features].
abstract: OBJECTIVE
  - To describe natural history of solitary bone plasmocytomas (SBO) after treatment.
  
  
  METHODS
  - Between 1975 and 1998, we retrospectively identified 13 patients with SBO treated in the department of radiotherapy at Salah-Azaïz institute of Tunis. To be included in this study, three criteria were needed: histologic confirmation and only one bone lesion without medullary infiltration (or less than 10%). Mean age was 43 years (22-64) with sex-ratio of 3,3. Tumor sites were vertebra (6), flat bones (6) and tibia (1). Megavoltage radiotherapy was given to all patients, associated to surgery in eight cases (5 excisions and 3 laminectomies) and to chemotherapy in three.
  
  
  RESULTS
  - With a mean follow-up of 63 months, two local failures were noted at 24 and 48 months. Two patients developed multifocal lesions and one patient had an extramedullary lesion. Multiple myeloma occurred in four patients (30%) after a median follow-up 3,5 years. Unfavorable outcome could not be predicted by age, gender or site of disease but by myeloma protein.
  
  
  CONCLUSIONS
  - Radiotherapy is an effective local treatment for solitary bone plasmocytoma. Prospective studies are needed to better define predictive parameters of unfavourable outcome and indications of combined chemotherapy.
authors.affiliation: Service de radiothérapie carcinologique, institut Salah-Azaïz, Bab-Saadoun, 1006 Tunis, Tunisie. lofti.kochbati@rns.tn
authors.forename: L
authors.initials: L
authors.lastname: Kochbati
authors.forename: N Kédidi
authors.initials: NK
authors.lastname: Ben Romdhane
authors.forename: K
authors.initials: K
authors.lastname: Mrad
authors.forename: C
authors.initials: C
authors.lastname: Nasr
authors.forename: D E
authors.initials: DE
authors.lastname: Ben Salah
authors.forename: K
authors.initials: K
authors.lastname: Ben Romdhane
authors.forename: M
authors.initials: M
authors.lastname: Maalej
mesh_terms: D000328:Adult; D001706:Biopsy; D001859:Bone Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D003037:Cobalt Radioisotopes / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007796:Laminectomy; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000209:etiology; D010954:Plasmacytoma / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D011867:Radioisotope Teletherapy; D011882:Radiotherapy, High-Energy; D012189:Retrospective Studies; D013125:Spinal Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D013977:Tibia / Q000473:pathology; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D003037:Cobalt Radioisotopes